Skip to ContentSkip to Navigation
Over ons Praktische zaken Waar vindt u ons dr. T.J.N. Hiltermann

Publicaties

Changes in global quality of life after treatment with immune checkpoint inhibitors in patients receiving different treatment regimens for advanced stage lung cancer in the Netherlands: a 2015-2021 cohort study

Chemoradiotherapy efficacy in patients with stage III non-small cell lung cancer (NSCLC): A prognostic clinical and biomarker-based model

CT-assessed sarcopenia and immune-related adverse events in patients with lung cancer: A competing risk time-to-event analysis

Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement

Lung cancer detection by electronic nose analysis of exhaled breath: a multi-center prospective external validation study

Novel immune checkpoint inhibitor strategies in advanced non-small cell lung cancer: towards biomarker-driven therapies?

Presence of On-Target Resistant Mutation in Pre-Treatment Samples of ALK Fusion Gene Positive Lung Cancer Patients

Quality of life, neurocognitive functioning, psychological issues, sexuality and comorbidity more than 2 years after commencing immune checkpoint inhibitor treatment

Real-world 5-year survival outcomes with durvalumab after chemoradiotherapy in unresectable, stage III NSCLC: Final data extraction from PACIFIC-R

Rising incidence of radiation pneumonitis after adjuvant durvalumab in NSCLC patients treated with concurrent chemoradiotherapy

Pers/media

TLCR Outstanding Author interview

Rilvegostomig Elicits Responses in CPI-Naive NSCLC, Irrespective of PD-L1 TPS Status

Terminaal zieke John Franke strijdt met podcast voor bevolkingsonderzoek naar longkanker

Primeur met TCR T-cellen

EERSTE LONGKANKERPATIËNT BEHANDELD MET GEMODIFICEERDE T-CELLEN Primeur met TCR T-cellen